Clinical Research Programs

Rheumatoid Arthritis

Corrona RA Questionnaire Based Research Observational Research Stud

Inclusion Criteria

Male or Female, at least 18 years of age

Able and willing to provide written consent for participation in the RA registry

Willing and able to provide Protected Health Information (PHI) which includes the following types of personal information at a minimum: 1)Full name and 2) DOB

Diagnosis of rheumatoid arthritis by a rheumatologist and meet one or more of the following criteria:

*Currently receiving an Eligible Medication** that was started within 365 days of the Enrollment Visit.

*Prescribed or receiving the first dose of an Eligible Medication** on the day of the Enrollment Visit.       

*Diagnosed with RA within 365 days of the Enrollment Visit regardless of treatment regimen

Exclusion Criteria

Diagnosed with Juvenile Idiopathic Arthritis (JIA), Psoriatic Arthritis (PSA), Spondyloarthritis(SPA), Ankylosing Spondylitis (AS), Systemic Lupus Erythematosus (SLE), or any other form of auto-immune inflammatory arthritis.

Participation in or planning to participate in a double-blind randomized clinical trial   of an RA drug. Of note, concurrent participation in another observational registry or unblinded Phase 3b/4 trial is not excluded.

                                                                                      RA BRIDGE

A Randomized, Active-Controlled, Parallel-Group, Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis


  • Have a diagnosis of adult-onset RA
    • At least 3/28 tender joints, and at least 3/28 swollen joints
    • at Visits 1 and 2
    • Inadequate response or intolerance to at least 1 DMARD
    • (biologic or synthetic)
    • If RA < 6 months, OK to enroll if patient is RF or CCP+ at screening
  • Have at least 1 of the following 4 characteristics:
    • Documented evidence of a VTE prior to this study
    • Age ≥60 years
    • BMI >30 kg/m2
    • Age 50 to <60 years AND BMI 25 to <30 kg/m2


  • Have any contraindications to a TNF inhibitor
  • Have a history of VTE (DVT/PE) within 12 weeks prior to randomization
  • OR have a history of recurrent (>1) VTE (DVT/PE)
  • Treatment with MORE THAN 1 PRIOR TNFi that was d/c for inadequate response for RA or intolerance (AE)
  • Treatment with >2 cDMARDs
  • Treatment with ANY JAK inhibitor
  • Treatment with any anticoagulant (ASA, Plavix OK)
  • Active recurrent malignancy <5 years prior to randomization (except cervical CA and nonmelanoma skin cancer/NMSC)


  • Patients will receive active drug regardless of randomization
  • Study participation lasts between 2.5 and 5.5 years

To Learn more about the RA Bridge Study, contact Tabitha 610-868-1336 ext. 110